您现在位置： -医药产业>>研究报告>>English reports>>English reports>> 浏览医药行业研究报告

Antasthmatic Market BreakDown Briefing

讯：

Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd Published: Format: Hardcopy and Adobe PDF Price: US$2,100 Contact: Mr. Bian chenghua Ms. Wu huifang Tel.: 86-10-68012929-2105/2101 Fax: 86-10-68052505 E-mail: bianch@healthoo.com wuhf@healthoo.com Table of contents Summary 1. Epidemiology of asthma and market scales 1.1 Morbidity rate 1.2 Market scales 2. Categories, mechanism of action and application of antasthmatic 2.1 Categories of antasthmatic 2.2 Mechanism of action and application of antasthmatic 3. Market scales and growth trend of antasthmatic 3.1 Drugs shares in hospital and growth rate from 2002 to 2005 3.2 Drugs shares of competitive enterprises in hospital from 2002 to 2005 3.3 Rank of antasthmatic from 2002 to 2005 4. Typical antasthmatic market breakdown 4.1 β receptor agonists Salbutamol Terbutaline Procaterol Salmeterol Formoterol Bambuterol 4.2 Phosphodiesterase inhibitors Theopylline Doxofylline Hyphylline Aminophylline 4.3 Anticholinergic agents Ipratropium Bromide 4.4 Leukotriene receptor antagonist Montelukast Zafirlukast 4.5 Glucocorticosteroid Budesonide Beclometasone Fluticasone propionate 4.6 Compound preparation Asmeton “strong” capsules Salmeterol Xinafoate and Fluticasone Propionate 5. Market scales and growth rate of key breeds 5.1 Market scales and growth rate of Budesonide 5.2 Market scales and growth rate of Salmeterol Xinafoate and Flutica sone Propionate 5.3 Market scales and growth rate of Formoterol 5.4 Market scales and growth rate of Montelukast 6. The appraisal of antasthmatic API demands in China 7. Development of new products 7.1 Application institution of new drugs 7.2 Introduction of developing new drugs which is not yet or about to China Appendix 1 Breeds of Basic Medical Insurance Medicine List in 2004 Appendix 2 Products of antasthmatic drugs approved by SFDA Tables and figures Table 1 Categories of antasthmatic drugs Table 2 Growth rate of sales values of Antasthmatic drugs from 2002 to 2005 Table 3 Antasthmatic drugs shares of enterprises from 2002 to 2005 Table 4 Top 20 best-selling Antiasthmatic drugs in 2005 Table 5 Top 20 best-selling Antiasthmatic drugs in 2004 Table 6 Top 20 best-selling Antiasthmatic drugs in 2003 Table 7 Top 20 best-selling Antiasthmatic drugs in 2002 Table 8 Top 10 Antiasthmatic drugs ranked by average annual growth from 2002 to 2005 Table 9 Top 20 leading enterprises for Salbutamol in 2005 Table 10 Top 20 leading enterprises for Terbutaline in 2005 Table 11 Top 20 leading enterprises for Procaterol in 2005 Table 12 Top 20 leading enterprises for Salmeterol in 2005 Table 13 Top 20 leading enterprises for Formoterol in 2005 Table 14 Top 20 leading enterprises for Bambuterol in 2005 Table 15 Top 20 leading enterprises for Theophylline in 2005 Table 16 Top 20 leading enterprises for Doxofylline in 2005 Table 17 Top 20 leading enterprises for Diprophylline in 2005 Table 18 Top 20 leading enterprises for Aminophylline in 2005 Table 19 Top 20 leading enterprises for Ipratropium Bromide in 2005 Table 20 Top 20 leading enterprises for Montelukast in 2005 Table 21 Top 20 leading enterprises for Zafirlukast in 2005 Table 22 Top 20 leading enterprises for Budesonide in 2005 Table 23 Top 20 leading enterprises for Beclometasone in 2005 Table 24 Top 20 leading enterprises for Fluticasone Propionate in 2005 Table 25 Top 20 leading enterprises for Asmeton “strong” Capsules in 2005 Table 26 Top 20 leading enterprises for Salmeterol Xinafoate and Fluticasone Propionate in 2005 Table 27 Sales values and growth rate of Budesonide of different enterprises from 2002 to 2005 Table 28 Sales values and growth rate of Salmeterol Xinafoate and Fluticasone Propionate of different enterprises from 2002 to 2005 Table 29 Sales values and growth rate of Formoterol of different enterprises from 2002 to 2005 Table 30 Sales values and growth rate of Montelukast of different enterprises from 2002 to 2005 Table 31 New drugs of Budesonide approved by SFDA from 2003 to 2006 Table 32 New drugs of Formoterol approved by SFDA from 2003 to 2006 Table 33 Antiasthmatic drugs of Basic Medical Insurance Medicine List in 2004 Figure 1 Sales values of Antiasthmatic drugs from 2002 to 2005 Figure 2 Market shares of major enterprises of Antiasthmatic drugs in 2005 Figure 3 Sales values and growth rate of Budesonide from 2002 to 2005 Figure 4 Sales values of Budesonide of enterprises from 2002 to 2005 Figure 5 Sales values and growth rate of Salmeterol Xinafoate and Fluticasone Propionate from 2002 to 2005 Figure 6 Sales values and growth rate of Formoterol from 2002 to 2005 Figure 7 Sales values of Formoterol of enterprises from 2002 to 2005 Figure 8 Sales values and growth rate of Montelukast from 2002 to 2005 Figure 9 Sales values of Montelukast of enterprises from 2002 to 2005